Bluejay Diagnostics director buys 12,500 BJDX shares

Bluejay Diagnostics director Fred S. Zeidman bought additional shares of the company’s stock.

Rhea-AI Filing Summary

Bluejay Diagnostics director Fred S. Zeidman bought additional shares of the company’s stock. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics common stock from the company in a private placement at $2.00 per share. Following this transaction, he directly owns 12,500 common shares.

Insider Trade Summary

Net Buyer: 12,500 shares

Net Buy 1 txn

Insider ZEIDMAN FRED S

Role Director

Bought 12,500 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$2.00	$25K

Holdings After Transaction: Common Stock — 12,500 shares (Direct)

Footnotes (1)

1. F1. On March 14, 2026, Mr. Zeidman purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share.

Key Figures

Shares purchased: 12,500 shares Purchase price: $2.00 per share Shares owned after transaction: 12,500 shares

3 metrics

Shares purchased 12,500 shares Common Stock bought on March 14, 2026

Purchase price $2.00 per share Private placement with issuer

Shares owned after transaction 12,500 shares Total direct holdings following purchase

Key Terms

private placement, Common Stock, open-market purchase

3 terms

private placement financial

"purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Bluejay Diagnostics (BJDX) report for Fred S. Zeidman?

Bluejay Diagnostics reported that director Fred S. Zeidman bought 12,500 shares of common stock. The purchase occurred on March 14, 2026, and was made directly from the company in a private placement rather than through the open market.

How many Bluejay Diagnostics (BJDX) shares did Fred S. Zeidman acquire and at what price?

Fred S. Zeidman acquired 12,500 shares of Bluejay Diagnostics common stock at $2.00 per share. This transaction was completed on March 14, 2026, in a private placement directly with the company, according to the Form 4 disclosure and related footnote.

Is Fred S. Zeidman a director of Bluejay Diagnostics (BJDX)?

Yes, Fred S. Zeidman is identified as a director of Bluejay Diagnostics. The Form 4 indicates his role as a director and shows he engaged in a direct purchase of 12,500 common shares in a private placement on March 14, 2026.

How many Bluejay Diagnostics (BJDX) shares does Fred S. Zeidman own after this transaction?

After the March 14, 2026 transaction, Fred S. Zeidman directly owns 12,500 shares of Bluejay Diagnostics common stock. The Form 4 lists this as his total direct holdings following the private placement purchase from the company at $2.00 per share.

Was the Bluejay Diagnostics (BJDX) insider purchase an open-market trade?

No, the transaction was not an open-market trade. A footnote explains that on March 14, 2026, Fred S. Zeidman purchased 12,500 shares of common stock directly from Bluejay Diagnostics in a private placement at a price of $2.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 05:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZEIDMAN FRED S

(Last) (First) (Middle)

C/O BLUEJAY DIAGNOSTICS, INC.

360 MASSACHUSETTS AVENUE, SUITE 203

(Street)

ACTON MASSACHUSETTS 01720

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		P		12,500(1)	A	$2	12,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 14, 2026, Mr. Zeidman purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share.

	/s/ Fred S Zeidman	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)